The work will focus on validating robust clinical end-points that can be used early in drug development to demonstrate pharmacodynamic activity of potential symptomatic and disease-modifying agents for AD in either healthy volunteers or patients, and thereby ultimately accelerate drug progression into clinical practice. These end-points will be based on enhanced understanding of the cognitive and neurophysiological impairments underlying normal ageing, mild cognitive impairment (MCI) and AD and also on novel markers identified from preclinical models of ageing and AD.